Expert Insights

Pasi Jänne, MD, shares insights about the recent FDA approval of trastuzumab deruxtecan for patients with HER2-mutant non-small cell lung cancer and the data that led to this approval.

Corey Langer, MD, provides an overview on the potential of tumor treatment fields for the treatment of advanced NSCLC, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.

David Tougeron, MD, reviews results from the PRODIGE 59-DURIGAST trial evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab as a second-line treatment for patients with advanced gastric or GEJ cancer.

Jonathan Rosenberg, MD, reviews findings from a cohort study evaluating enfortumab vedotin monotherapy or enfortumab vedotin in combination with pembrolizumab for cisplatin-ineligible patients with urothelial cancer.

Matthew Goetz, MD, highlights findings from the ELAINE 1 trial exploring lasofoxifene vs fulvestrant for patients with ESR1-mutated locally advanced or metastatic breast cancer who progressed on aromatase and CDK4/6 inhibitors.

Keiichi Fujiwara, MD, PhD, discusses findings from a phase 3 trial that evaluated maintenance chemotherapy with tegafur-uracil compared to observation following concurrent chemoradiotherapy in patients with locally advanced cervical cancer.

Edward Garon, MD, MS, provides an overview on the basics of immunotherapy for NSCLC and SCLC, a topic he presented at the virtual 2022 GDU Lung Cancers meeting.

Matthew Goetz, MD, discusses a second interim analysis on OS results for the MONARCH 3 trial, demonstrating prolonged OS with the addition of abemaciclib to a nonsteroidal aromatase inhibitor in patients with HR-positive, HER2-negative...

Benjamin Levy, MD, reviews his talk on targeted therapies for patients with MET-dependent lung cancers, presented at the virtual 2022 GDU Lung Cancers meeting.

Bernd Kasper, MD, PhD, discusses findings from the phase 3 DeFi trial, in which nirogacestat demonstrated a 71% reduction in the risk of disease progression or death vs placebo in patients with progressing desmoid tumors.